- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04118959
Role of Atosiban in Recurrent Implantation Failure (RIF)
The Value of Atosiban on the Day of Embryo Transfer in Patients With Recurrent Implantation Failure
Study Overview
Status
Conditions
Detailed Description
ET is a critical step of an IVF cycle that merits the utmost attention. Its success depends on the frequency of uterine contractions, the endometrial receptivity and the quality of embryos transferred.
Uterine contractions are the most fundamental constituents of the uterine receptivity. Excessive contractions may decrease the implantation potential of embryos by expelling the embryos from the uterus. Studies have revealed a six-fold increase in uterine contractility in IVF cycles when measured before ET as compared to the condition before ovulation in natural cycles. Excessive manipulation of the cervix such as the use of tenaculum during difficult ET can also trigger uterine contractions, consequently leading to failure of embryo implantation.
IVF success rates have been potentially improved by the use of drugs that inhibit pronounced uterine contractions at the time of ET. Treatment strategies such as the use of beta-agonists or nonsteroidal anti-inflammatory agents for tocolysis have not been beneficial in IVF-ET procedures.
Atosiban is a combined oxytocin/vasopressin V1A antagonist. It functions mainly by blocking oxytocin and vasopressin V1a receptors to decrease the frequency and amplitude of uterine contractions, which enhances implantation and pregnancy rates. RIF remains unexplained in most cases, which results in considerable variation in how RIF is treated and managed. Atosiban competes with oxytocin at oxytocin receptors in endometrial cells and inhibits oxytocin-induced PGF2α release, thus inhibiting uterine contractions and increasing chances of embryo implantation and may add value in improving the outcome in RIF patients.
Recently published studies showed that atosiban inhibits oxytocin-induced PGF2α and uterine contractility, consequently leading to improved IRs. Studies have shown a considerable reduction in the frequency of uterine contractions before and after the administration of atosiban in women undergoing ET.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Kamal eldin Rageh, M.D.
- Phone Number: 0097333153871
- Email: dr_kamal_rageh@yahoo.com
Study Contact Backup
- Name: Ahmed Barakat, FRCOG
- Phone Number: 0097317727888
- Email: ahmed.barakat@yahoo.com
Study Locations
-
-
Manama
-
Adliya, Manama, Bahrain, 15006
- Recruiting
- Al-BARAKA FERTILITY HOSPITAL
-
Contact:
- AHMED BARAKAT, FRCOG
- Phone Number: 0097336660500
- Email: ahmed_barakat@yahoo.com
-
Contact:
- Kamal Rageh, M.D
- Phone Number: 0097333153871
- Email: dr_kamal_rageh@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women 22-40 years age
- Body mass index- 18.5-30 kg/m 2
- The normal uterine cavity on ultrasound scan
- At least one good quality embryo present for transfer
- Endometrium thickness ≥7.5 mm with endometrial volume 2-2.5 ml and good endometrial and subendometrial vascularity.
Exclusion Criteria:
- 1. Women ≥ 40 years age 2. Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids, hydrosalpinx, and adenomyosis) 3. Patients at risk of ovarian hyperstimulation syndrome 4. Patients with a history of hypersensitivity to atosiban 5. Endocrine dysfunction 6. Major organ dysfunction such as liver or kidney failure.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pregnancy rate
Time Frame: 2 weeks
|
B- HCG
|
2 weeks
|
clinical pregnancy rate
Time Frame: 4 weeks
|
positive fetal heart beats
|
4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K.Rageh
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Implantation Failure
-
Mehdi YousefiCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Kasr El Aini HospitalUnknownRecurrent Implantation Failure
-
Dr. Kamal RagehCompleted
-
SCARM Institute, Tabriz, IranCompleted
-
Tabriz University of Medical SciencesCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Shanghai First Maternity and Infant HospitalUnknownRecurrent Implantation FailureChina
-
Assistance Publique - Hôpitaux de ParisRecruitingRecurrent Unexplained Implantation FailureFrance
-
TopLab Company for ART Laboratories Consultation...CompletedRecurrent Implantation Failure (RIF)
-
ShangHai Ji Ai Genetics & IVF InstituteRecruitingAcupuncture | Recurrent Implantation FailureChina
-
Universitaire Ziekenhuizen KU LeuvenRecruitingRecurrent Implantation FailureBelgium